Pathology Discovery

Pathology Discovery

ISSN 2052-7896
Case report

Abnormal expression of CD79a, CD56 and CD7 in acute myeloid leukemia

Ghaleb Elyamany1*, kamal Fadalla2 and Abdulaziz Al Abdulaaly2

*Correspondence: Ghaleb Elyamany

1. Theodor Bilharz Research Institute, Department of Hematology and Blood Bank, Egypt.

Author Affiliations

2. Department of Adult Clinical Hematology and Stem cell Therapy, Prince Sultan Military Medical City, Saudi Arabia.


Background: Flow cytometric analysis of leukemias improves accuracy for distinguishing acute leukemias of myeloid and lymphoid origin. In rare cases, both myeloid and lymphoid antigens are expressed, creating ambiguity for lineage assignment and difficulties in diagnosis of leukemia. Aberrant antigen expression in acute myeloid leukemia (AML) is recognized to be a poor prognostic indicator. CD79a is a highly lineage-specific marker of B lymphoid cells and plays an important role in the diagnosis of acute leukemia.

Methods: We report an unusual case of acute myeloid leukemia in which CD79a is clearly expressed along with other lymphoid antigens (CD7 and CD56) in addition to antigens denoting myeloid lineage. The characteristics of morphology, immunophenotype, molecular and cytogenetic of bone marrow samples were analyzed.

Results: This is an unusual case of AML shows that, CD79 expression in acute leukemia is not restricted to B-ALL and is rarely aberrantly expressed in AML.

Conclusions: The high score given to CD79a by EGIL is questionable based on cytogenetic classification. The prognostic relevance of expression of CD79a in AML is unclear and need further studies. The prognostic significance of selected markers of leukemic cells is well known, CD7 and CD56 expression at diagnosis has been associated with low remission rates and biological aggressiveness in a significant proportion of acute leukemias.

Keywords: Acute myeloid leukemia, CD79a aberrant expression, CD56 and CD7

ISSN 2052-7896
Volume 1
Abstract Download